Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | G6PD | P11413 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21687676 | 0.97 | ALDH1A1 (0.37) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21687484 | 0.94 | STS (0.36) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21687672 | 0.91 | STS (0.36) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21687669 | 0.91 | ALDH1A1 (0.40) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21688094 | 0.91 | ALDH1A1 (0.39) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21688072 | 0.89 | ALDH1A1 (0.35) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21687816 | 0.88 | ALDH1A1 (0.42) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21687673 | 0.88 | ALDH1A1 (0.37) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21687666 | 0.88 | ALDH1A1 (0.36) | ALDH1A1LMNAHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL21688031 | 0.87 | G6PD (0.36) | ALDH1A1G6PDTDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11201300-B2 | Condensed cyclic compound and organic light-emitting device including condensed cyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-12-14 | — | — | US | disclosed |
| US-20200044168-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200044168-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND | CRY1, CCNL2, CCNE2 | ALDH1A1 616/4885LMNA 1582/4885HPGD 2175/4885 |
| US-11201300-B2 | Condensed cyclic compound and organic light-emitting device including condensed cyclic compound | CRY1, CCNL2, CCNE2 | ALDH1A1 616/4885LMNA 1582/4885HPGD 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.